Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 193

1.

Acute exacerbation of idiopathic pulmonary fibrosis: International survey and call for harmonisation.

Kreuter M, Polke M, Walsh SLF, Krisam J, Collard HR, Chaudhuri N, Avdeev S, Behr J, Calligaro G, Corte T, Flaherty K, Funke-Chambour M, Kolb M, Kondoh Y, Maher TM, Molina MM, Morais A, Moor CC, Morisset J, Pereira C, Quadrelli S, Selman M, Tzouvelekis A, Valenzuela C, Vancheri C, Vicens-Zygmunt V, Wälscher J, Wuyts W, Wijsenbeek M, Cottin V, Bendstrup E.

Eur Respir J. 2020 Feb 14. pii: 1901760. doi: 10.1183/13993003.01760-2019. [Epub ahead of print]

PMID:
32060068
2.

Patient gender bias on the diagnosis of idiopathic pulmonary fibrosis.

Assayag D, Morisset J, Johannson KA, Wells AU, Walsh SLF.

Thorax. 2020 Feb 13. pii: thoraxjnl-2019-213968. doi: 10.1136/thoraxjnl-2019-213968. [Epub ahead of print]

PMID:
32054644
3.

Opioid use disorder.

Strang J, Volkow ND, Degenhardt L, Hickman M, Johnson K, Koob GF, Marshall BDL, Tyndall M, Walsh SL.

Nat Rev Dis Primers. 2020 Jan 9;6(1):3. doi: 10.1038/s41572-019-0137-5. Review.

PMID:
31919349
4.

Gabapentin drug misuse signals: A pharmacovigilance assessment using the FDA adverse event reporting system.

Vickers-Smith R, Sun J, Charnigo RJ, Lofwall MR, Walsh SL, Havens JR.

Drug Alcohol Depend. 2020 Jan 1;206:107709. doi: 10.1016/j.drugalcdep.2019.107709. Epub 2019 Nov 2.

PMID:
31732295
5.

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.

Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK; INBUILD Trial Investigators.

N Engl J Med. 2019 Oct 31;381(18):1718-1727. doi: 10.1056/NEJMoa1908681. Epub 2019 Sep 29.

PMID:
31566307
6.

US physicians' decision-making during buprenorphine-naloxone treatment: Conjoint analyses of dose and office visit adjustments based on patient progress.

Knudsen HK, Lofwall MR, Lin LA, Walsh SL, Studts JL.

Drug Alcohol Depend. 2019 Nov 1;204:107490. doi: 10.1016/j.drugalcdep.2019.05.022. Epub 2019 Aug 30.

PMID:
31518885
7.

Demystifying fibrotic hypersensitivity pneumonitis diagnosis: it's all about shades of grey.

Walsh SLF, Richeldi L.

Eur Respir J. 2019 Jul 25;54(1). pii: 1900906. doi: 10.1183/13993003.00906-2019. Print 2019 Jul. No abstract available.

PMID:
31345989
8.

Outpatient Parenteral Antimicrobial Therapy Plus Buprenorphine for Opioid Use Disorder and Severe Injection-Related Infections.

Fanucchi LC, Walsh SL, Thornton AC, Nuzzo PA, Lofwall MR.

Clin Infect Dis. 2019 Jul 18. pii: ciz654. doi: 10.1093/cid/ciz654. [Epub ahead of print]

PMID:
31342057
9.

Deploying science to change hearts and minds: Responding to the opioid crisis.

Walsh SL, Long KQX.

Prev Med. 2019 Nov;128:105780. doi: 10.1016/j.ypmed.2019.105780. Epub 2019 Jul 15.

PMID:
31319116
10.

Integrated outpatient treatment of opioid use disorder and injection-related infections: A description of a new care model.

Fanucchi LC, Walsh SL, Thornton AC, Lofwall MR.

Prev Med. 2019 Nov;128:105760. doi: 10.1016/j.ypmed.2019.105760. Epub 2019 Jun 26.

PMID:
31251946
11.

Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis.

Walsh SLF, Lederer DJ, Ryerson CJ, Kolb M, Maher TM, Nusser R, Poletti V, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown KK, Corte TJ, Cottin V, Crestani B, Flaherty KR, Glaspole IN, Grutters J, Inoue Y, Kondoh Y, Kreuter M, Johannson KA, Ley B, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Selman M, Spagnolo P, Taniguchi H, Tomassetti S, Valeyre D, Wijsenbeek M, Wuyts WA, Wells AU.

Am J Respir Crit Care Med. 2019 Nov 1;200(9):1146-1153. doi: 10.1164/rccm.201903-0493OC.

12.

A randomized, double-blind, placebo-controlled study of the kappa opioid receptor antagonist, CERC-501, in a human laboratory model of smoking behavior.

Jones JD, Babalonis S, Marcus R, Vince B, Kelsh D, Lofwall MR, Fraser H, Paterson B, Martinez S, Martinez DM, Nunes EV, Walsh SL, Comer SD.

Addict Biol. 2019 Jun 26:e12799. doi: 10.1111/adb.12799. [Epub ahead of print]

PMID:
31240842
13.

Cannabinoid modulation of opioid analgesia and subjective drug effects in healthy humans.

Babalonis S, Lofwall MR, Sloan PA, Nuzzo PA, Fanucchi LC, Walsh SL.

Psychopharmacology (Berl). 2019 Nov;236(11):3341-3352. doi: 10.1007/s00213-019-05293-1. Epub 2019 Jun 15.

PMID:
31201479
14.

Visual and Automated CT Measurements of Lung Volume Loss in Idiopathic Pulmonary Fibrosis.

Robbie H, Wells AU, Jacob J, Walsh SLF, Nair A, Srikanthan A, Tazoniero P, Devaraj A.

AJR Am J Roentgenol. 2019 Aug;213(2):318-324. doi: 10.2214/AJR.18.20884. Epub 2019 May 7.

PMID:
31063425
15.

Impact of health reform on health insurance status among persons who use opioids in eastern Kentucky: A prospective cohort analysis.

Knudsen HK, Lofwall MR, Walsh SL, Havens JR.

Int J Drug Policy. 2019 Aug;70:8-14. doi: 10.1016/j.drugpo.2019.04.008. Epub 2019 May 1.

PMID:
31054372
16.

The characterisation of interstitial lung disease multidisciplinary team meetings: a global study.

Richeldi L, Launders N, Martinez F, Walsh SLF, Myers J, Wang B, Jones M, Chisholm A, Flaherty KR.

ERJ Open Res. 2019 Apr 1;5(2). pii: 00209-2018. doi: 10.1183/23120541.00209-2018. eCollection 2019 Apr.

17.

Subclinical Interstitial Lung Abnormalities: Lumping and Splitting Revisited.

Walsh SLF, Richeldi L.

Am J Respir Crit Care Med. 2019 Jul 15;200(2):121-123. doi: 10.1164/rccm.201901-0180ED. No abstract available.

18.

Perceived need and availability of psychosocial interventions across buprenorphine prescriber specialties.

Lin LA, Lofwall MR, Walsh SL, Knudsen HK.

Addict Behav. 2019 Jun;93:72-77. doi: 10.1016/j.addbeh.2019.01.023. Epub 2019 Jan 16.

PMID:
30690416
19.

Quantitative analysis of lung sounds for monitoring idiopathic pulmonary fibrosis: a prospective pilot study.

Sgalla G, Larici AR, Sverzellati N, Bartholmai B, Walsh SLF, Nikolic D, Barney A, Fletcher S, Jones M, Davies DD, Richeldi L.

Eur Respir J. 2019 Mar 7;53(3). pii: 1802093. doi: 10.1183/13993003.02093-2018. Print 2019 Mar. No abstract available.

PMID:
30578384
20.

Role of imaging in progressive-fibrosing interstitial lung diseases.

Walsh SLF, Devaraj A, Enghelmayer JI, Kishi K, Silva RS, Patel N, Rossman MD, Valenzuela C, Vancheri C.

Eur Respir Rev. 2018 Dec 21;27(150). pii: 180073. doi: 10.1183/16000617.0073-2018. Print 2018 Dec 31. Review.

21.

Buprenorphine Pharmacology Review: Update on Transmucosal and Long-acting Formulations.

Coe MA, Lofwall MR, Walsh SL.

J Addict Med. 2019 Mar/Apr;13(2):93-103. doi: 10.1097/ADM.0000000000000457.

PMID:
30531584
22.

Variable radiological lung nodule evaluation leads to divergent management recommendations.

Nair A, Bartlett EC, Walsh SLF, Wells AU, Navani N, Hardavella G, Bhalla S, Calandriello L, Devaraj A, Goo JM, Klein JS, MacMahon H, Schaefer-Prokop CM, Seo JB, Sverzellati N, Desai SR; Lung Nodule Evaluation Group; Lung Nodule Evaluation Group.

Eur Respir J. 2018 Dec 20;52(6). pii: 1801359. doi: 10.1183/13993003.01359-2018. Print 2018 Dec.

PMID:
30409817
23.

Mediastinal Lymphadenopathy in Interstitial Lung Disease. Time to Be Counted.

Walsh SLF.

Am J Respir Crit Care Med. 2019 Mar 15;199(6):685-687. doi: 10.1164/rccm.201810-1892ED. No abstract available.

24.

Deep learning for classifying fibrotic lung disease on high-resolution computed tomography: a case-cohort study.

Walsh SLF, Calandriello L, Silva M, Sverzellati N.

Lancet Respir Med. 2018 Nov;6(11):837-845. doi: 10.1016/S2213-2600(18)30286-8. Epub 2018 Sep 16.

PMID:
30232049
25.

Radiological diagnosis of interstitial lung disease: is it all about pattern recognition?

Walsh SLF, Kolb M.

Eur Respir J. 2018 Aug 16;52(2). pii: 1801321. doi: 10.1183/13993003.01321-2018. Print 2018 Aug. No abstract available.

26.

MoodNetwork: An Innovative Approach to Patient-centered Research.

Sylvia LG, Hearing CM, Montana RE, Gold AK, Walsh SL, Janos JA, Tovey RE, Deckersbach T, Nierenberg AA.

Med Care. 2018 Oct;56 Suppl 10 Suppl 1:S48-S52. doi: 10.1097/MLR.0000000000000789.

27.

In-hospital illicit drug use, substance use disorders, and acceptance of residential treatment in a prospective pilot needs assessment of hospitalized adults with severe infections from injecting drugs.

Fanucchi LC, Lofwall MR, Nuzzo PA, Walsh SL.

J Subst Abuse Treat. 2018 Sep;92:64-69. doi: 10.1016/j.jsat.2018.06.011. Epub 2018 Jun 22.

PMID:
30032946
28.

Imaging biomarkers and staging in IPF.

Walsh SLF.

Curr Opin Pulm Med. 2018 Sep;24(5):445-452. doi: 10.1097/MCP.0000000000000507. Review.

PMID:
30015679
29.

Computed Tomographic Biomarkers in Idiopathic Pulmonary Fibrosis. The Future of Quantitative Analysis.

Wu X, Kim GH, Salisbury ML, Barber D, Bartholmai BJ, Brown KK, Conoscenti CS, De Backer J, Flaherty KR, Gruden JF, Hoffman EA, Humphries SM, Jacob J, Maher TM, Raghu G, Richeldi L, Ross BD, Schlenker-Herceg R, Sverzellati N, Wells AU, Martinez FJ, Lynch DA, Goldin J, Walsh SLF.

Am J Respir Crit Care Med. 2019 Jan 1;199(1):12-21. doi: 10.1164/rccm.201803-0444PP. No abstract available.

30.

Implementing Treatment of Opioid-Use Disorder in Rural Settings: a Focus on HIV and Hepatitis C Prevention and Treatment.

Havens JR, Walsh SL, Korthuis PT, Fiellin DA.

Curr HIV/AIDS Rep. 2018 Aug;15(4):315-323. doi: 10.1007/s11904-018-0402-3. Review.

31.

"Velcro-type" crackles predict specific radiologic features of fibrotic interstitial lung disease.

Sgalla G, Walsh SLF, Sverzellati N, Fletcher S, Cerri S, Dimitrov B, Nikolic D, Barney A, Pancaldi F, Larcher L, Luppi F, Jones MG, Davies D, Richeldi L.

BMC Pulm Med. 2018 Jun 18;18(1):103. doi: 10.1186/s12890-018-0670-0.

32.

Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial.

Lofwall MR, Walsh SL, Nunes EV, Bailey GL, Sigmon SC, Kampman KM, Frost M, Tiberg F, Linden M, Sheldon B, Oosman S, Peterson S, Chen M, Kim S.

JAMA Intern Med. 2018 Jun 1;178(6):764-773. doi: 10.1001/jamainternmed.2018.1052.

33.

Predicting Outcomes in Idiopathic Pulmonary Fibrosis Using Automated Computed Tomographic Analysis.

Jacob J, Bartholmai BJ, Rajagopalan S, van Moorsel CHM, van Es HW, van Beek FT, Struik MHL, Kokosi M, Egashira R, Brun AL, Nair A, Walsh SLF, Cross G, Barnett J, de Lauretis A, Judge EP, Desai S, Karwoski R, Ourselin S, Renzoni E, Maher TM, Altmann A, Wells AU.

Am J Respir Crit Care Med. 2018 Sep 15;198(6):767-776. doi: 10.1164/rccm.201711-2174OC.

34.

Perceptions and practices addressing diversion among US buprenorphine prescribers.

Lin LA, Lofwall MR, Walsh SL, Gordon AJ, Knudsen HK.

Drug Alcohol Depend. 2018 May 1;186:147-153. doi: 10.1016/j.drugalcdep.2018.01.015. Epub 2018 Mar 10.

35.

Bioavailability and Pharmacokinetics of Oral Cocaine in Humans.

Coe MA, Jufer Phipps RA, Cone EJ, Walsh SL.

J Anal Toxicol. 2018 Jun 1;42(5):285-292. doi: 10.1093/jat/bky007.

36.

Reply to Moodley: A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease.

Ryerson CJ, Walsh SLF, Collard HR; all authors.

Am J Respir Crit Care Med. 2018 May 15;197(10):1366-1367. doi: 10.1164/rccm.201712-2515LE. No abstract available.

PMID:
29342368
37.

Pulmonary hypertension in interstitial lung disease: Limitations of echocardiography compared to cardiac catheterization.

Keir GJ, Wort SJ, Kokosi M, George PM, Walsh SLF, Jacob J, Price L, Bax S, Renzoni EA, Maher TM, MacDonald P, Hansell DM, Wells AU.

Respirology. 2018 Jul;23(7):687-694. doi: 10.1111/resp.13250. Epub 2018 Jan 12.

38.

Examining the Feasibility and Acceptability of an Online Yoga Class for Mood Disorders: A MoodNetwork Study.

Uebelacker L, Dufour SC, Dinerman JG, Walsh SL, Hearing C, Gillette LT, Deckersbach T, Nierenberg AA, Weinstock L, Sylvia LG.

J Psychiatr Pract. 2018 Jan;24(1):60-67. doi: 10.1097/PRA.0000000000000286.

PMID:
29320386
39.

Transbronchial Cryobiopsies for the Diagnosis of Diffuse Parenchymal Lung Diseases: Expert Statement from the Cryobiopsy Working Group on Safety and Utility and a Call for Standardization of the Procedure.

Hetzel J, Maldonado F, Ravaglia C, Wells AU, Colby TV, Tomassetti S, Ryu JH, Fruchter O, Piciucchi S, Dubini A, Cavazza A, Chilosi M, Sverzellati N, Valeyre D, Leduc D, Walsh SLF, Gasparini S, Hetzel M, Hagmeyer L, Haentschel M, Eberhardt R, Darwiche K, Yarmus LB, Torrego A, Krishna G, Shah PL, Annema JT, Herth FJF, Poletti V.

Respiration. 2018;95(3):188-200. doi: 10.1159/000484055. Epub 2018 Jan 9.

40.

Likelihood of pulmonary hypertension in patients with idiopathic pulmonary fibrosis and emphysema.

Jacob J, Bartholmai BJ, Rajagopalan S, Karwoski R, Nair A, Walsh SLF, Barnett J, Cross G, Judge EP, Kokosi M, Renzoni E, Maher TM, Wells AU.

Respirology. 2018 Jun;23(6):593-599. doi: 10.1111/resp.13231. Epub 2017 Dec 13.

41.

Unclassifiable-interstitial lung disease: Outcome prediction using CT and functional indices.

Jacob J, Bartholmai BJ, Rajagopalan S, Egashira R, Brun AL, Kokosi M, Nair A, Walsh SLF, Karwoski R, Nicholson AG, Hansell DM, Wells AU.

Respir Med. 2017 Sep;130:43-51. doi: 10.1016/j.rmed.2017.07.007. Epub 2017 Jul 14.

42.

Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis: An International Modified Delphi Survey.

Morisset J, Johannson KA, Jones KD, Wolters PJ, Collard HR, Walsh SLF, Ley B; HP Delphi Collaborators.

Am J Respir Crit Care Med. 2018 Apr 15;197(8):1036-1044. doi: 10.1164/rccm.201710-1986OC. Epub 2017 Nov 27.

43.

Individualized Progress Measures Are More Acceptable to Clinicians Than Standardized Measures: Results of a National Survey.

Jensen-Doss A, Smith AM, Becker-Haimes EM, Mora Ringle V, Walsh LM, Nanda M, Walsh SL, Maxwell CA, Lyon AR.

Adm Policy Ment Health. 2018 May;45(3):392-403. doi: 10.1007/s10488-017-0833-y.

PMID:
29143173
44.

Serial automated quantitative CT analysis in idiopathic pulmonary fibrosis: functional correlations and comparison with changes in visual CT scores.

Jacob J, Bartholmai BJ, Rajagopalan S, Kokosi M, Egashira R, Brun AL, Nair A, Walsh SLF, Karwoski R, Wells AU.

Eur Radiol. 2018 Mar;28(3):1318-1327. doi: 10.1007/s00330-017-5053-z. Epub 2017 Sep 29.

PMID:
28963678
45.

Physicians' Decision-making When Implementing Buprenorphine With New Patients: Conjoint Analyses of Data From a Cohort of Current Prescribers.

Knudsen HK, Lofwall MR, Walsh SL, Havens JR, Studts JL.

J Addict Med. 2018 Jan/Feb;12(1):31-39. doi: 10.1097/ADM.0000000000000360.

46.

Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study.

Walsh SLF, Maher TM, Kolb M, Poletti V, Nusser R, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown K, Calandriello L, Corte TJ, Cottin V, Crestani B, Flaherty K, Glaspole I, Grutters J, Inoue Y, Kokosi M, Kondoh Y, Kouranos V, Kreuter M, Johannson K, Judge E, Ley B, Margaritopoulos G, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Ryerson CJ, Selman M, Spagnolo P, Taniguchi H, Tomassetti S, Valeyre D, Wijsenbeek M, Wuyts W, Hansell D, Wells A; IPF Project Consortium.

Eur Respir J. 2017 Aug 31;50(2). pii: 1700936. doi: 10.1183/13993003.00936-2017. Print 2017 Aug.

47.

A mixed methods study of HIV-related services in buprenorphine treatment.

Knudsen HK, Cook J, Lofwall MR, Walsh SL, Studts JL, Havens JR.

Subst Abuse Treat Prev Policy. 2017 Aug 16;12(1):37. doi: 10.1186/s13011-017-0122-5.

48.

Imaging for Sarcoidosis.

Calandriello L, Walsh SLF.

Semin Respir Crit Care Med. 2017 Aug;38(4):417-436. doi: 10.1055/s-0037-1603765. Epub 2017 Jul 27. Review. No abstract available.

PMID:
28750458
49.

Functional and prognostic effects when emphysema complicates idiopathic pulmonary fibrosis.

Jacob J, Bartholmai BJ, Rajagopalan S, Kokosi M, Maher TM, Nair A, Karwoski R, Renzoni E, Walsh SLF, Hansell DM, Wells AU.

Eur Respir J. 2017 Jul 5;50(1). pii: 1700379. doi: 10.1183/13993003.00379-2017. Print 2017 Jul.

50.

Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial.

Walsh SL, Comer SD, Lofwall MR, Vince B, Levy-Cooperman N, Kelsh D, Coe MA, Jones JD, Nuzzo PA, Tiberg F, Sheldon B, Kim S.

JAMA Psychiatry. 2017 Sep 1;74(9):894-902. doi: 10.1001/jamapsychiatry.2017.1874.

Supplemental Content

Loading ...
Support Center